CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
中枢神经系统复发弥漫大 B 细胞淋巴瘤经 CAR-T 细胞治疗后使用靶向治疗的持久缓解
英文原题：Prolonged Responses in Central Nervous System Relapsed Diffuse Large B-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy Using Targeted Treatments.
查看英文原题
Prolonged Responses in Central Nervous System Relapsed Diffuse Large B-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy Using Targeted Treatments.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞（CAR-T 细胞）疗法的引入改变了弥漫性大B细胞淋巴瘤（DLBCL）的治疗格局。然而，该疗法后复发后的最佳治疗策略仍需阐明。在本报告中，我们描述了一例67岁男性患者，在接受tisagenlecleucel作为三线治疗后复发。我们介绍了复发后的治疗方法，其中我们尝试维持循环中的CAR-T 细胞。这反映在这些治疗期间CAR-T 细胞的动力学中。
展开英文摘要原文
The introduction of chimeric antigen receptor T-cell (CAR-T cell) therapy has changed the treatment landscape of diffuse large B-cell lymphoma (DLBCL).
However, the optimal treatment strategy after relapse after this therapy still needs to be elucidated. In this report, we describe the case of a 67-year-old male who relapsed after treatment with tisagenlecleucel as a third-line therapy.
We present our approach to treatment after relapse, in which we tried to sustain the circulating chimeric antigen receptor T-cells. This is reflected by the kinetics of the chimeric antigen receptor T-cells during these treatments.
论文信息
- 作者
- Planken S、Faict S、Trullemans F、Linskens E、Vandepoele K、De Becker A
- 单位
- Department of Hematology, Universitair Ziekenhuis Brussel, Jette, BEL.
- 文献类型
- 病例报告
- 期刊
- Cureus2024 Aug
- 原文标识
- PubMed 39108768 · DOI 10.7759/cureus.66291
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →